Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

ACE inhibition may decrease diabetes risk by boosting the impact of bradykinin on adipocytes.

M F McCarty1

  • 1Pantox Laboratories, San Diego, California 92109, USA.

Medical Hypotheses
|April 18, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Calcium supplementation, renin, and vascular risk.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2012
Same author

Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells.

British journal of cancer·2005
Same author

The putative therapeutic value of high-dose selenium in proliferative retinopathies may reflect down-regulation of VEGF production by the hypoxic retina.

Medical hypotheses·2004
Same author

Effects of overexpression of ephrin-B2 on tumour growth in human colorectal cancer.

British journal of cancer·2004
Same author

ZD6126 inhibits orthotopic growth and peritoneal carcinomatosis in a mouse model of human gastric cancer.

British journal of cancer·2004
Same author

A shift in myocardial substrate, improved endothelial function, and diminished sympathetic activity may contribute to the anti-anginal impact of very-low-fat diets.

Medical hypotheses·2004

Angiotensin-converting enzyme (ACE) inhibitor therapy may prevent type 2 diabetes by enhancing insulin sensitivity in fat and muscle tissues. This mechanism, involving bradykinin, offers a new strategy for diabetes prevention in at-risk populations.

Area of Science:

  • Cardiovascular Medicine
  • Endocrinology
  • Pharmacology

Background:

  • Angiotensin-converting enzyme (ACE) inhibitors are primarily used for hypertension and heart failure.
  • Previous research suggests bradykinin potentiation by ACE inhibitors may influence insulin sensitivity.
  • Insulin resistance in adipocytes contributes to the development of type 2 diabetes.

Purpose of the Study:

  • To investigate the potential of ACE inhibitor therapy in preventing type 2 diabetes in non-diabetic patients.
  • To elucidate the underlying mechanisms by which ACE inhibitors might reduce diabetes risk.

Main Methods:

  • Analysis of findings from the HOPE trial.
  • Review of existing evidence on bradykinin, B2 receptors, and insulin signaling.
  • Exploration of the role of tyrosine phosphatase in insulin receptor activity.

Related Experiment Videos

Main Results:

  • The HOPE trial suggests ACE inhibitors reduce type 2 diabetes risk in non-diabetic individuals.
  • Bradykinin, via B2 receptors, may enhance insulin responsiveness in adipocytes and muscle.
  • ACE inhibitors increase bradykinin availability, potentially improving insulin signaling.

Conclusions:

  • ACE inhibition favorably impacts adipocyte insulin responsiveness and bradykinin's action on skeletal muscle, explaining diabetes prevention.
  • Orally active, food-derived ACE inhibitors (e.g., Katsuobushi oligopeptides) offer a feasible approach for widespread diabetes prevention.
  • ACE inhibitor therapy may offer a dual benefit of diabetes prevention and cardiovascular risk reduction.